NGeneBio Co., Ltd. (KOSDAQ: 354200)

Market Cap	31.77B
Revenue (ttm)	4.99B
Net Income (ttm)	-13.28B
Shares Out	12.89M
EPS (ttm)	-1,035.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	128,308
Open	2,540.00
Previous Close	2,565.00
Day's Range	2,480.00 - 2,610.00
52-Week Range	2,180.00 - 9,800.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About NGeneBio

NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors; HLAaccuTest, an in vitro diagnostic ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 102
• Stock Exchange: KOSDAQ
• Ticker Symbol: 354200

Financial Performance

In 2023, NGeneBio's revenue was 4.35 billion, a decrease of -60.51% compared to the previous year's 11.02 billion. Losses were -12.77 billion, 30.5% more than in 2022.